Daniel Starczynowski: Uncovering a new mechanism behind chemotherapy resistance in AML
Daniel Starczynowski, Professor at Cincinnati Children’s Hospital Medical Center, shared on LinkedIn:
“We’re excited to share our latest paper in Nature Communications uncovering a new mechanism behind chemotherapy resistance in AML.
Huge congratulations to lead author Ashley Cochran for leading this groundbreaking work!
We’re thankful to our collaborators and to CancerFreeKids, the University of Cincinnati, and Cincinnati Children’s Hospital for their support.
Despite decades of treatment with chemotherapy and extensive research, the reason why some AML patients initially respond while others are refractory to chemotherapy remains unresolved.
Our study reveals that the NF-kB target gene A20 plays a key role in chemotherapy failure.
By disrupting A20, we were able to restore sensitivity to chemotherapy treatment through necroptosis, a non-apoptotic cell death pathway. A20 prevents necroptotic cell death, making it a novel therapeutic target for resistant AML.
This research provides valuable insight into why some AML patients don’t respond to chemotherapy and opens new doors for potential treatments targeting necroptosis.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023